Biosimilars in Immunology
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Europe leads the way for immunology biosimilars in the 7MM, and India is at the forefront in the emerging markets. In terms of immunology biosimilar penetration, the 5EU and India demonstrate the highest favorability towards uptake of biosimilars.
Japan and South Korea have an intermediate biosimilar penetration index, while the US market is the least favorable towards biosimilars. Pricing is a key issue for expensive-to-develop biosimilars entering an increasingly crowded autoimmune disease market.Biosimilars are intended to relieve healthcare-associated cost burden; however, the economic effects of incorporating them into clinical practice are unclear, due to increased time and staff costs required for switching patients onto biosimilars.
Pricing can be a differentiating strategy among different biosimilars and larger discounts over originator brands can boost greater uptake of specific biosimilars. Quotas dictate prescribing patterns in the 5EU; however, physicians show concern about switching to a biosimilar from the originator brand. The majority of KOLs interviewed by GlobalData indicated that they used biosimilars mostly for new patients. KOLs also cited reluctance to switch existing patients to biosimilars, highlighting that they did not want to change a biologic treatment that was working for the patient.
Other reasons against switching included lack of incentives for physicians, lack of switching data, and nocebo effects.Biogen, Sandoz, Pfizer, and Amgen are dominating the immunology biosimilars field. The immunology biosimilars space is dominated in developed markets by established brand names, including Biogen, Sandoz, Pfizer, and Amgen.
In India and South Korea, major biosimilar players include Celltrion, Cipla, and Zydus Cadila.
Scope
Components of the report include:
Introduction to Biosimilars in Immunology – Defining biosimilars in immunology and discussing the history of drugs approved across the 9MM.
Assessment of Marketed and Pipeline Products – An overview of biosimilar products on the market and drugs currently in clinical development.
Regulatory Strategies – Overview of biosimilar regulatory strategies by country.
Market Dynamics – Overview of biosimilar market dynamics by country.
Focus Indications and Market Potential – In-depth assessment of biosimilars in major autoimmune indications, market potential as well as drivers and barriers to uptake.
Key Players – In-depth assessment of key players in the space across the 9MM
Key Clinical and Commercial Concepts – An examination of key clinical and commercial concepts in the biosimilars in immunology space, based on KOL and payer insights. Pricing and reimbursement infrastructure and challenges are examined.
Future Opportunities – Overview of future strategies recommended by KOLs and payers for boosting biosimilar uptake is discussed.
Amgen
Alexion
Johnson & Johnson
Novartis
Bristol Myers Squib
Takeda
Sanofi
Roche
Pfizer
UCB
Biogen
Sandoz
Hetero Pharmaceuticals
Mylan
Biocon
Cipla
Zydus Cadila
Fresenius Kabi
Samsung Bioepsis
Intas
Fujifilm
Merck
Mochida
Lupin
Celltrion
YDr. Reddy's
Torrent Pharma
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.